linjc16/ctgov huggingface dataset:
Targeting ER-Golgi Homeostasis in an Advantageous Therapeutic Strategy in Lung Cancer

Study Overview
=================
Brief Summary
-----------------
Lung cancer remains the most common cause of cancer-related death in the world. The major advances in treatment of lung cancer have brought only minor improvements in survival therefore novel systemic treatment methods are urgently needed. Protein levels are regulated by the protein homeostasis network that generates and protects the protein fold (ER and Golgi included). The heat shock protein 90 (Hsp90) is an essential molecular chaperon involved in the posttranslational folding and stability of proteins. Hsp90 inhibition leads to accumulation of unfolded proteins and ER stress. The therapeutic efficacy of such inhibition may be augmented by co-administering it with other drugs that disrupt ER-Golgi homeostasis like histone deacetylase (HDAC) or proteasome inhibitors. ER-Golgi homeostasis disruption affects a wide network of proteins and pathways as such affords a systemic target. Thus, the investigators aimed to examine the effect of combined treatment of Hsp90 antagonist with proteasome or HDAC inhibitors on human lung cancer cell lines and primary cells.

Official Title
-----------------
Targeting ER-Golgi Homeostasis in an Advantageous Therapeutic Strategy in Lung Cancer

Conditions
-----------------
The Combined Effect of Hsp90 Inhibitor and HDAC/Proteasome Inhibitors on Lung Cancer Cell Fate and ER-Golgi Homeostasis Will be Examined.

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: PATIENTS WITH PROVED DIAGNOSIS OF LUNG CARCINOMA THAT ARE CANDIDATS FOR RADICAL SURGICAL TREATMENT Exclusion Criteria: PATIENTS WITH SUSPICION FOR LUNG CARCINOMA WITHOUT PATHOLOGYCAL DIAFNOSIS BEFORE SURGERY

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| malignant neoplasm's cells<br> | |
| natural cells<br> | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
A Study for PRO of CML in Real Word

Study Overview
=================
Brief Summary
-----------------
Successful outcomes in CML require both prolonged adherence to oral TKI therapy by patients and careful monitoring of treatment responses by their physicians. Patient Reported Outcomes(PRO) assessment is important to facilitate decisions in the current treatment landscape of CML.

Detailed Description
-----------------
Above 18 years of age. Patient with confirmed diagnosis of Philadelphia chromosome positive and/or BCR-ABL positive chronic myeloid leukemia (CML). Written informed consent. Patients enrolled in investigational drug-trials or other type of clinical trials are also eligible.

Official Title
-----------------
Validation Value of the Questionnaire to Assess Health-related Quality of Life in Patients With CML

Conditions
-----------------
CML (Chronic Myelogenous Leukemia)

Intervention / Treatment
-----------------
* Other: questionnaire


Participation Criteria
=================

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| CML patient<br>≥18 years old CML patiente | Other: questionnaire<br>* PHQ-9 and GAD-7 questionnaire<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Assess health-related Quality of Life and Symptom Burden in patients with chronic myeloid leukemia | Health-related quality of life (HRQOL) assessment in the current treatment landscape of chronic myeloid leukemia | 1 year |
The Effect of Allergen Immunotherapy on Exhaled Nitric Oxide in Adult Patients With Asthma and Allergic Rhinitis

Study Overview
=================
Brief Summary
-----------------
This study will evaluate whether exhaled nitric oxide levels are affected by allergen immunotherapy (allergy shots). The investigators' hypothesis is that successful allergen immunotherapy may be accompanied by decreased exhaled nitric oxide levels.

Official Title
-----------------
The Effect of Allergen Immunotherapy on Exhaled Nitric Oxide in Adult Patients With Asthma and Allergic Rhinitis

Conditions
-----------------
Allergic Asthma, Allergic Rhinitis

Intervention / Treatment
-----------------
* Biological: Allergen immunotherapy


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Subjects over 18 years old with allergic asthma and/or allergic rhinitis who are beginning allergen desensitization Exclusion Criteria: Smokers Subjects of dimished capacity

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Subjects on allergen immunotherapy<br>Measurements of Nitric Oxide by NIOX MINO. This device is now FDA approved. | Biological: Allergen immunotherapy<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Effect of allergen immunotherapy on exhaled nitric oxide |  | One year |
The Effect of Caudal Block on Optic Nerve Sheath Diameter in Pediatric Patients

Study Overview
=================
Brief Summary
-----------------
Caudal epidural block has been a widely used regional anesthesia method, especially in pediatric surgery, to provide intraoperative and postoperative analgesia. Studies on non-invasive methods used for intracranial pressure measurement have shown that optic nerve sheath diameter is related to intracranial pressure. Optic nerve sheath diameter measurement has high diagnostic accuracy for detecting increased intracranial pressure in children. The aim of the study is to investigate the effect of the caudal block on optic nerve sheath diameter in pediatric patients.

Official Title
-----------------
The Effect of Caudal Block on Optic Nerve Sheath Diameter in Pediatric Patients

Conditions
-----------------
Postoperative Pain, Intracranial Hypertension

Intervention / Treatment
-----------------
* Drug: Bupivacaine Hydrochloride


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: circumcision, inguinal hernia, undescended testis, hydrocele operation Exclusion Criteria: neurological or spinal anomaly, coagulopathy allergy to local anesthetics, local infection in the area to be intervention, with increased intracranial pressure children with any ophthalmic pathology

Ages Eligible for Study
-----------------
Minimum Age: 1 Year
Maximum Age: 7 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Diagnostic
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: Group Caudal<br>Caudal block with 1 ml / kg, % 0.25 bupivacaine | Drug: Bupivacaine Hydrochloride<br>* 1 ml / kg, % 0.25 bupivacaine<br>|
| No Intervention: Group Control<br>No intervention | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Optic Nerve Diameter | Consecutive Optic Nerve Sheath Diameter Measurement from Both Eyes | First minute | 
| Optic Nerve Diameter | Consecutive Optic Nerve Sheath Diameter Measurement from Both Eyes | 5th minutes | 
| Optic Nerve Diameter | Consecutive Optic Nerve Sheath Diameter Measurement from Both Eyes | 15th minutes | 
| Optic Nerve Diameter | Consecutive Optic Nerve Sheath Diameter Measurement from Both Eyes | 30th minutes |
Comparison Between Low Dose and High Dose Intra-articular Tranexamic Acid in Total Knee Arthroplasty

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to compare blood loss between using low dose (500 mg) and high dose (3 g) topical intra-articular tranexamic acid after total knee arthroplasty in double-blind RCT

Official Title
-----------------
Topical Intra-Articular High Doses Compared With Low Doses of Tranexamic Acid to Reduce Blood Loss in Primary Total Knee Arthroplasty: A Double-Blind Randomized Controlled Trial

Conditions
-----------------
Blood Loss, Surgical

Intervention / Treatment
-----------------
* Drug: Tranexamic Acid


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Osteoarthritic knee who underwent primary total knee arthroplasty Exclusion Criteria: Abnormal coagulation or bleeding disorder Allergy to tranexamic acid History of thromboembolism or ischemic heart disease or cerebrovascular accident chronic kidney disease stage 3-4

Ages Eligible for Study
-----------------
Minimum Age: 50 Years
Maximum Age: 90 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Low dose<br>single dose of intra-articular Tranexamic acid 500 miligrams | Drug: Tranexamic Acid<br>* IA (intra-articular) tranexamic acid after capsule closure<br>|
| Active Comparator: High dose<br>Single dose of intra-articular Tranexamic acid 3 grams | Drug: Tranexamic Acid<br>* IA (intra-articular) tranexamic acid after capsule closure<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Total blood loss | Blood loos that calculated from Haemoglobin drop at 72 hours after surgery | 72 hours after TKA | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Blood transfusion | incidence of blood transfusion after surgery | 0-72 hours after surgery | 
| Rate of participants with thromboembolism | Clinical thromboembolism after surgery | At 72 hours and 2 weeks after surgery | 
| Rate of participants with infection | Superficial or deep infection after TKA | 0-3 months after surgery | 
| Knee ROM | Range of motion of the knee | At 2, 6 weeks after surgery | 
| Functional score | Modified WOMAC | At 6 weeks after surgery | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Blood loss, Tranexamic acid, Total knee arthroplasty, Topical administration
Specific Immunotherapy With Recombinant Birch Pollen Allergen rBet v1-FV

Study Overview
=================
Brief Summary
-----------------
Specific immunotherapy with recombinant birch pollen allergen rBet v1-FV

Official Title
-----------------
A Bicentre Open Label Randomised Pilot Study for Proof of Safety and Efficacy of Immunotherapy With an Aluminium Hydroxide-adsorbed Recombinant Hypoallergenic Derivative of the Major Birch Pollen Allergen Bet v 1-FV Versus a Depot Extract of Natural Birch Allergen

Conditions
-----------------
Birch Pollen Allergy

Intervention / Treatment
-----------------
* Biological: Recombinant birch pollen


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Positive RAST result to birch pollen Positive Skin Prick Test reaction to birch pollen positive nasal provocation test result to birch pollen extract Exclusion Criteria: serious chronic diseases other relevant seasonal allergies

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 60 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Biological: Recombinant birch pollen|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Allergy, Birch pollen, Recombinant
HPV-test, Cervical Cancer and Follow-up

Study Overview
=================
Brief Summary
-----------------
The investigators have planned this project to evaluate the follow-up program after surgery due to cervical cancer and to explore the possibilities for different tests of Human Papilloma Virus (HPV) in contributing to the customization of the follow-up program. Purpose: The investigators effort is to provide the background for an evidence-based update of the follow-up program after surgery due to cervical cancer with the purpose of early diagnosis of recurrence affecting quality of life for as few women as possible.

Official Title
-----------------
Recurrence After Surgery for Cervical Cancer - an Evaluation of the Follow-up Program.

Conditions
-----------------
Uterine Cervical Neoplasms, Recurrence, Human Papilloma Virus

Intervention / Treatment
-----------------
* Procedure: Human Papilloma Virus test from the vaginal vault


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Surgery. FIGO stage IA-IB. > 18 years Exclusion Criteria: Ajuvant oncologic treatment

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Human Papilloma Virus test<br>Patients treated with surgery alone for uterine cervical neoplasms attending surveillance at Dept. of Obstetrics and Gynecology, Oncogynecological unit, Aarhus University Hospital from 01.01.14 From 01.01.15 patients will be recruited from Oncogynecologic units at Aalborg University Hospital and Rigshospitalet. Recruitment of patients from these institutions has not been successful and has been closed. It is expected due to political decisions that the cervical cancer patients from the uptake area of Aalborg University Hospital will be treated at Aarhus University Hospital and they will then be eligible for the study | Procedure: Human Papilloma Virus test from the vaginal vault<br>* Surveillance after surgical treatment of early stage cervical cancer<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Prevalence of HPV Genotypes in Vagina (Type 16, 18 and Other) |  | 2 years | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| HPV Clearance From Vagina in Between the Two Planned Follow-up Visits. |  | 2 years | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Surveillance, Follow up
Atrial Fibrillation in Young Patients: a Prospective Multicentre Registry

Study Overview
=================
Brief Summary
-----------------
Atrial fibrillation is a rare cardiac arrhythmia in young (i.e. <= 35-year-old) patients. Etiological factors, current management and mid- to long-term outcomes remain unknown.

Detailed Description
-----------------
Atrial Fibrillation in YOUNG patients (YOUNG-AF) is a prospective, observational, multicentric registry, including every consecutive patients aged < 35-year-old with a diagnosis of atrial fibrillation. The registry will assess demographical, physical activity, toxicologic and genetic factors, as well as current management regarding anticoagulation, anti-arrhythmic drugs and catheter ablation. As an observational registry, patient will be managed with the guidelines-directed standard-of-care.

Official Title
-----------------
Atrial Fibrillation in Young Patients: a Prospective Multicentre Registry

Conditions
-----------------
Atrial Fibrillation, Lone Atrial Fibrillation

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: First episode of atrial fibrillation Less than 35-year-old Diagnostic by 12-lead ECG or continuous monitoring (minimal duration 30 seconds) French Social Security number Exclusion Criteria: Transvenous cardiac implantable electronic device (insertable cardiac monitors are not an exclusion criteria)

Ages Eligible for Study
-----------------
Maximum Age: 35 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Composite of mortality, thromboembolic event and heart failure | Incidence of all-cause mortality, symptomatic thromboembolic event and congestive heart failure at 10-year after initial diagnosis of atrial fibrillation. | at 10-year | 
| Recurrent symptomatic atrial fibrillation. | Incidence of symptomatic atrial fibrillation at 10-year after initial diagnosis of atrial fibrillation. | at 10-year | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Atrial Fibrillation, Lone Atrial Fibrillation
Epidermal Growth Factor Receptor (EGFR) Status Based Gefitinib Neoadjuvant Therapy in Non Small Cell Lung Cancer (NSCLC)

Study Overview
=================
Brief Summary
-----------------
This study aims to investigate the efficacy and safety of gefitinib as neoadjuvant therapy in stage IIIA NSCLC patients.

Official Title
-----------------
Phase II Study of EGFR Status Based Gefitinib Neoadjuvant Therapy in NSCLC Patients

Conditions
-----------------
Non Small Cell Lung Cancer

Intervention / Treatment
-----------------
* Drug: gefitinib


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients pathological diagnosed with NSCLC,with EGFR sensitive mutation; Stage IIIA patients with technical operable disease evaluated by image and lab results; Patients without chemotherapy or targeted-therapy before; Inform Consent. Exclusion Criteria: Patients with malignant tumor other than lung cancer; Patients with other diseases such as cardiovascular disease that may hamper follow up; Patients that may not coordinate well,judged by researcher.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Gefitinib, Neoadjuvant therapy<br>Patients with EGFR mutation will be recruited and treated with gefitinib. | Drug: gefitinib<br>* Patients with EGFR mutation in exon 19 or 21 will be administrated with gefitinib as neoadjuvant therapy. Then evaluated for response and then operation for operable patients.<br>* Other names: Iressa;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Response Rate |  | 1 month | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Non Small Cell Lung Cancer, Gefitinib, Neoadjuvant Therapy
Comfort Evaluation of a New MPS vs. Replenish in Contact Lens Patients

Study Overview
=================
Brief Summary
-----------------
To compare corneal staining after contact lens instillation with a new MPS vs. RepleniSH

Conditions
-----------------
Corneal Staining

Intervention / Treatment
-----------------
* Other: new MPS
* Other: RepleniSH


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients 18 yrs or older Males or females Any race or ethnic background CL patients using MPS products currently Patients using Contact Lenses habitually (at least 1 month) Exclusion Criteria: Corneal refractive surgery within 6 months of this study. Contact lens use on day of examination. Corneal ectasia. Current use of Restasis

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------

Design Details

Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Single


Arms and Interventions

| Intervention/Treatment |
| --- |
|Other: new MPS|nan|
|Other: RepleniSH|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
Intravenous Immunoglobulin in Prevention of Preterm Neonatal Sepsis

Study Overview
=================
Brief Summary
-----------------
Majority of healthcare authorities believe that due to the methodological weakness and small number of patients in conducted therapeutic trials, the evidences are insufficient to support the efficacy of intravenous immunoglobulin (IVIG) in prevention of preterm neonatal sepsis. The objective of this research is to determine the effect of intravenous immunoglobulin in prevention of preterm neonatal sepsis.

Official Title
-----------------
Effect of Intravenous Immunoglobulin in Prevention of Preterm Neonatal Sepsis

Conditions
-----------------
Neonatal Sepsis

Intervention / Treatment
-----------------
* Drug: IVIG


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Born alive before 37 weeks of pregnancy (preterm neonates) Under 2500 g at birth Exclusion Criteria: lethal anomaly congenital heart disease TORCH infection severe asphyxia

Ages Eligible for Study
-----------------
Minimum Age: 1 Day
Maximum Age: 7 Days

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: IVIG<br>IVIG at a dose of 500mg/kg within 12 h and 3 days of birth | Drug: IVIG<br>* IVIG at a dose of 500mg/kg within 12 h and 3 days of birth<br>|
| No Intervention: Control<br>No intervention | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Mortality | Death from sepsis or its related complications | 7 days | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Total number of days of hospitalization | Duration of hospitalization | 7 days | 
| Intraventricular Hemorrhage | occurrence of Intraventricular Hemorrhage | 7 days | 
| Necrotizing enterocolitis | occurrence of Necrotizing enterocolitis | 7 days | 
| Bronchopulmonary dysplasia | occurrence of Bronchopulmonary dysplasia | 7 days |